NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biotech’

23 April 2014

OrbiMed leads $22m round for Aerpio Therapeutics

biotech_lrg Biopharmaceutical startup Aerpio Therapeutics has secured $22m in a round led by venture capital firm OrbiMed.

22 April 2014

Vivo Capital leads $58.5m Series D for ProNAi Therapeutics

biotech_lrg Nucleic acid therapeutics developer ProNAi Therapeutics has secured $59.5m in a Series D round led by venture capital firm Vivo Capital.

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

15 April 2014

Column Group nears $200m mark for second fund

biotech_lrg Biotech-focused investment firm The Column Group has passed the halfway mark for its $250m-targeting second venture capital fund, according to documents filed with US securities regulators.

8 April 2014

Deerfield secures $1.6bn for third fund

Healthcare-focused investment firm Deerfield Management Company has secured $1.6bn for its third fund.

8 April 2014

Lightstone Ventures secures more than $150m for debut fundp

life science test tube_sq Life sciences-focused venture capital firm Lightstone Ventures has passed the halfway mark for its debut fund, AltAssets has learned.

3 April 2014

Intarcia Therapeutics scores $200m round

biotech_lrg Venture capital firm RA Capital has led a massive $200m round for biotech startup Intarcia Therapeutics.

24 March 2014

Venture capital-backed Versartis soars after IPO

graph_positive_170sq Venture capital-backed Versartis soars after IPO

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

11 March 2014

Lumena Pharmaceuticals raises $45m in NEA-led Series B

biotech_lrg New Enterprise Associates led a $45m Series B round for biopharmaceutical company Lumena Pharmaceuticals, which is focused on developing products for rare cholestatic liver diseases and serious metabolic disorders.

Page 1 of 812345...Last »

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014